Since <i>RAS</i> or <i>RAF</i> mutations occur frequently in low-grade serous carcinoma and lead to constitutively activated MAPK cascade, MEK inhibition should be effective in the treatment of low-grade serous carcinoma. The gene discussed is MAP2K7; the disease is serous adenocarcinoma.